Fabry disease. Role of the dermatologist and therapeutic advance;Maladie de Fabry. Place du dermatologue et progrès thérapeutiques

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 2, 2005, Pages 171-176

  Mahe E ^a,b   Hadj Rabia, S ^a   Chauveau, D ^a   De Prost, Y ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; CARBAMAZEPINE; GABAPENTIN; PHENYTOIN;

ANHIDROSIS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FABRY DISEASE; GENETIC ASSOCIATION; HEMANGIOKERATOMA; HUMAN; PARESTHESIA; PATHOPHYSIOLOGY; PRENATAL DIAGNOSIS; REVIEW; DERMATOLOGY; DIFFERENTIAL DIAGNOSIS; PHYSICIAN ATTITUDE;

DERMATOLOGY; DIAGNOSIS, DIFFERENTIAL; FABRY DISEASE; HUMANS; PHYSICIAN'S ROLE;

EID: 15044347537     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(05)79234-6     Document Type: Review

References (21)

1. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-46.
2. Germain DP. Maladie de Fabry (déficit en alpha-galactosidase A): physiopathologie, signes cliniques et aspects génétiques. J Soc Biol 2002; 196:161-73.
3. Lidove O, Joly D, Barbey F, Bletry O, Grunfeld JP. Maladie de Fabry chez l'adulte: aspects cliniques et thérapeutiques. Rev Med Interne 2001; 22 Suppl:384S-392S.
4. Mohrenschlager M, Braun-Falco M, Ring J, Abeck D. Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol 2003;4:189-96.
5. Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 2000;84:361-5.
6. Kang WH, Chun SI, Lee S. Generalized anhidrosis associated with Fabry's disease. J Am Acad Dermatol 1987;17:883-7.
7. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60.
8. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75.
9. Grunfeld JP, Lidove O, Joly D, Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis 2001;24 (Suppl 2):71-4.
10. Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002;3:10.
11. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
12. Schiffmann R, Fleeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-10.
13. Hajioff D, Enever Y, Quiney R, Zuckerman J, MacDermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-94.
14. Tondel C, Laegreid LM, Hirth A, Houge G, Mansson JE, Sovik O. [Intravenous enzyme substitution therapy in children with Fabry's disease]. Tidsskr Nor Laegeforen 2003;123: 3388-90. (Abstract)
15. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
16. De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplan 2003;18:33-5.
17. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301.
18. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003;26:617-27.
19. Breunig F, Wanner C. Enzyme replacement therapy for Fabry disease: proving the clinical benefit. Nephrol Dial Transplant 2003;18:7-9.
20. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32.
21. Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 2001;98:2676-81.